GW&K Investment Management LLC Has $30.35 Million Holdings in AtriCure, Inc. $ATRC

GW&K Investment Management LLC trimmed its position in AtriCure, Inc. (NASDAQ:ATRC) by 14.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 861,035 shares of the medical device company’s stock after selling 147,305 shares during the quarter. GW&K Investment Management LLC’s holdings in AtriCure were worth $30,352,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd grew its holdings in shares of AtriCure by 197.1% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 811 shares of the medical device company’s stock worth $29,000 after purchasing an additional 538 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in AtriCure during the second quarter worth $37,000. Farther Finance Advisors LLC increased its holdings in AtriCure by 1,818.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,132 shares of the medical device company’s stock valued at $40,000 after buying an additional 1,073 shares during the period. First Horizon Corp acquired a new position in shares of AtriCure in the 3rd quarter valued at $42,000. Finally, CWM LLC raised its stake in shares of AtriCure by 36.6% in the 3rd quarter. CWM LLC now owns 2,587 shares of the medical device company’s stock valued at $91,000 after buying an additional 693 shares in the last quarter. Institutional investors own 99.11% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ATRC shares. Oppenheimer lowered shares of AtriCure from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 18th. JPMorgan Chase & Co. downgraded shares of AtriCure from an “overweight” rating to a “neutral” rating and set a $36.00 price target on the stock. in a research report on Wednesday, February 11th. Wall Street Zen upgraded shares of AtriCure from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 21st. Citigroup reaffirmed an “outperform” rating on shares of AtriCure in a research note on Wednesday, February 18th. Finally, Canaccord Genuity Group reduced their target price on shares of AtriCure from $64.00 to $53.00 and set a “buy” rating on the stock in a research report on Wednesday, February 18th. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $48.43.

AtriCure Price Performance

Shares of ATRC stock opened at $30.31 on Friday. The firm’s 50 day moving average price is $36.48 and its two-hundred day moving average price is $36.41. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.99 and a current ratio of 3.96. AtriCure, Inc. has a 52-week low of $28.29 and a 52-week high of $43.18. The stock has a market cap of $1.51 billion, a PE ratio of -126.29 and a beta of 1.42.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Tuesday, February 17th. The medical device company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.10. AtriCure had a negative net margin of 2.14% and a negative return on equity of 1.15%. The company had revenue of $140.50 million during the quarter, compared to analysts’ expectations of $140.50 million. During the same quarter in the previous year, the company posted ($0.33) EPS. The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. As a group, analysts forecast that AtriCure, Inc. will post -0.6 EPS for the current year.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.